Morgan Stanley Maintains Overweight on Alumis, Raises Price Target to $38

3/20/2026
Impact: 75
Healthcare

Morgan Stanley analyst Terence Flynn has maintained an Overweight rating on Alumis (NASDAQ: ALMS) and increased the price target from $33 to $38. This adjustment reflects a positive outlook for the company's performance.

AI summary, not financial advice

Share: